Doxorubicin induces biphasic neurotoxicity to rat cortical neurons

NeuroToxicology

Volumn 29, Issue 2, 2008, Pages 286-293

  Lopes, Miguel Ângelo ^a,b   Meisel, Andreas ^b   Dirnagl, Ulrich ^b   Carvalho, Félix Dias ^a   Bastos, Maria de Lourdes ^a  

^a Faculty of Medicine   (Portugal)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Caspase 3; CNS; Cortical neurons; Doxorubicin; Necrosis; ROS

Indexed keywords

BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; DOXORUBICIN;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CELLS, CULTURED; CEREBRAL CORTEX; CYCLOHEXIMIDE; CYSTEINE PROTEINASE INHIBITORS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME ACTIVATION; NECROSIS; NEURONS; OLIGOPEPTIDES; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, WISTAR; TIME FACTORS;

RATTUS;

EID: 39749200035     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2007.12.003     Document Type: Article

References (29)

1. Armstrong M.B., Bian X., Liu Y., Subramanian C., Ratanaproeska A.B., Shao F., et al. Signaling from p53 to NF-κB determines the chemotherapy responsiveness of neuroblastoma. Neoplasia 8 (2006) 964-974
2. Bezombes C., de Thonel A., Apostolou A., Louat T., Jaffrezou J.P., Laurent G., et al. Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation. Mol Pharmacol 62 (2002) 1446-1455
3. Bigotte L., Arvidson B., and Olsson Y. Cytofluorescence localization of adriamycin in the nervous system: distribution of the drug in the central nervous system adult mice after intravenous injection I. Acta Neuropathol 57 (1982) 121-129
4. Binaschi M., Bigioni M., Cipollone A., Rossi C., Coso C., Maggi C.A., et al. Anthracyclines: selected new developments. Curr Med Chem 1 (2001) 113-130
5. Braun J.S., Novak R., Murray P.J., Eischer C.M., Kroemer G., Halle A., et al. Apoptosis-Inducing Factor mediates microglial and neuronal apoptosis caused by Pneumococcus. J Infect Dis 184 (2001) 1301-1309
6. Brewer G.J. Serum free B27/NBM supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum and dentate gyrus. J Neurosci Res 42 (1995) 674-683
7. Bruer U., Weih M.K., Isaev N.K., Meisel A., Ruscher K., Bergk A., et al. Induction of tolerance in rat cortical neurons: hypoxic preconditioning. FEBS Lett 414 (1997) 117-121
8. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57 (1999) 727-741
9. Guano F., Pourquier P., Tinelli S., Binaschi M., Animati F., Manzini S., et al. Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol 56 (1999) 77-84
10. Harms C., Lautenschlager M., Bergk A., Freyer D., Weih M., Dirnagl U., et al. Melatonin is protective in necrotic but not in caspase-dependent, free radical-independent apoptotic neuronal cell death in primary neuronal cultures. FASEB J 14 (2000) 1814-1824
11. Harms C., Lautenschlager M., Bergk A., Katchanov J., Freyer D., Kapinya K., et al. Differential mechanisms of neuroprotection by 17 β-Estradiol in apoptotic versus necrotic neurodegeneration. J Neurosci 21 8 (2001) 2600-2609
12. Kim R., Tanabe K., Uchida Y., Emi M., Inoue H., and Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50 (2002) 343-353
13. Koh J.Y., and Choi D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 20 (1987) 83-90
14. Laurent G., and Jaffrezou J.P. Signaling pathways by daunorubicin. Blood 98 (2001) 913-924
15. Liu C., Takemasa A., Liles W., Goodman R., Jonas M., Rosen H., et al. Broad-spectrum Caspase inhibition paradoxally augments cell death in TNF-α-stimulated neutrophils. Blood 101 (2003) 295-304
16. 2 induced caspase-3-independent degradation of Akt/protein kinase B. J Biol Chem 277 (2002) 42943-42952
17. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56 (2004) 185-229
18. Myers C.E. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25 Suppl. 10 (1998) 10-14
19. Penault-Lorca F., Cayre A., Bouchet Mishellany F., Amat S., Feillel V., Le Bouedec G., et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22 (2003) 1319-1325
20. Perego P., Corna E., De Cesare M., Gatti L., Polizzi P., Pratesi G., Supino R., and Zunino F. Role os apoptosis and apoptotic-related genes in cellular response and antitumor efficacyof anthracyclins. Cur Med Chem 8 (2001) 31-37
21. Petri B., Bootz A., Khalansky A., Hekmatara T., Muller R., Uhl R., et al. Chemotherapy of brain tumour using doxorubicin bound to surfactantcoated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Controlled Release 117 1 (2006) 51-58
22. Ruiz-Ruiz C., Robledo G., Cano E., Redondo J.M., and Lopez-Rivas A. Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumour cells. J Biol Chem 278 (2003) 31667-31675
23. Ruscher K., Freyer D., Karsch M., Isaev N., Megow D., Sawitzki B., et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 22 (2002) 10291-10301
24. Stearns V., Singh B., Tsangaris T., Crawford J.G., Novielli A., Ellis M.J., et al. A prospective pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9 (2003) 124-133
25. Tilloy S., Monnaert V., Fenart L., Bricout H., Cecchelli R., and Monflier E. Methylated [beta]-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier. Bioorg Med Chem Lett 16 (2006) 2154-2157
26. Wetzel M., Rosenberg G.A., and Cunningham L.A. Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur J Neurosci 18 (2003) 1050-1060
27. Wetzel M., Tibbitts J., Rosenberg G.A., and Cunningham L.A. Vulnerability of mouse cortical neurons to doxorubicin-induced apoptosis is strain-dependent and is correlated with mRNAs encoding Fas, Fas-Ligand, and metalloproteinases. Apoptosis 9 (2004) 649-656
28. Wu J., Harris N.L., and Inge T.H. Nuclear factor-kappa B and apoptosis inducing factor activation by doxorubicin analog WP744 in SH-SY5Y neuroblastoma cells. J Surg Res 122 (2004) 231-239
29. Zunino F., Pratesi G., and Perego P. Role of the sugar moyety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol 61 (2001) 933-938